$5.89
0.305.37%
Last update: Oct 27, 3:34 AM
Cytek Biosciences Inc
CTKBNASDAQ
Cytek Biosciences (CTKB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Cytek Biosciences (CTKB) last issued guidance on August 5, 2026 for fiscal year 2026. The company guided revenue in the range of $207M - $212M for the period.
Compared to prior guidance, Cytek Biosciences maintained its revenue forecast from a prior range of $205M - $212M.
Cytek Biosciences has issued 22 guidance updates between November 9, 2022 and August 5, 2026. During this period, the company raised its outlook 5 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.02 | $-0.09 | $-0.01 | $-0.01 |
| Actual | $-0.09 | $-0.15 | $-0.34 | $-0.04 |
| Surprise | -350.0% | -66.7% | -3300.0% | -300.0% |
| Revenue | ||||
| Estimate | $48.5M | $44.2M | $58.8M | $51.2M |
| Actual | $48.1M | $44.1M | $62.1M | $52.3M |
| Surprise | -0.81% | -100.0% | +5.68% | +2.04% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.07 | $-0.02 | $-0.08 | $-0.02 |
| Revenue | ||||
| Consensus | $52.9M | $63.7M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.09 | $-0.02 | -350.0 % |
| Q1 | May 7, 2026 | $-0.15 | $-0.09 | -66.7 % |
| Q4 | Feb 26, 2026 | $-0.34 | $-0.01 | -3300.0 % |
| Q3 | Nov 5, 2025 | $-0.04 | $-0.01 | -300.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $48.14M | $48.53M | -0.81 % |
| Q1 | May 7, 2026 | $44.14M | $44.22M | -100.0 % |
| Q4 | Feb 26, 2026 | $62.14M | $58.80M | 5.68 % |
| Q3 | Nov 5, 2025 | $52.29M | $51.25M | 2.04 % |
